Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project

Inclusion Criteria

• •1. Patients must have histologically or cytologically confirmed adenocarcinoma of the colon.
• •2. Patients must have metastatic disease to the liver with at least one lesion that is measurable by RECIST criteria within 4 weeks prior to entry of study
• •3. Patients with a history of colon adenocarcinoma treated by surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of \> 5 years has elapsed between the primary surgery and the development of metastatic disease. Clinicians should consider biopsy of lesions to establish diagnosis of metastatic colon adenocarcinoma if there is substantial clinical ambiguity regarding the nature or source of apparent metastases.
• •4. Patients must have ECOG performance status of 0-2
• •5. Patients must be \>= 18 years of age
• •6. Laboratory values \<= 2 weeks prior to enrollment:
• •* Absolute Neutrophil Count (ANC) \>= 1.5 x 10\^9/L (\>= 1500/mm\^3)
• •* Platelets (PLT) \>= 100 x 10\^9/L \>= 100,000/mm\^3)
• •* Hemoglobin (Hgb) \>= 9 g/dL
• •* Serum creatinine \<= 1.5 ULN
• •* Serum bilirubin \<= 1.5 ULN
• •* Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) \<= 3.0 x ULN (\<= 5 x ULN if liver metastases present). Note: ERCP or percutaneous stenting may be used to normalize the liver function tests.
• •* Negative for proteinuria based on dip stick reading OR, if documentation of +1 result for protein on dip stick reading, then total urinary protein \<= 500 mg and measured creatinine clearance (CrCl) \>= 50 mL/min from a 24-hour urine collection
• •7. Life expectancy \>= 12 weeks
• •8. Ability to give written informed consent according to local guidelines